Safety and feasibility of transulnar cardiac catheterization.

Recently, ulnar artery cannulation has been described as an alternative to the transfemoral and radial approaches to vascular access for cardiac catheterization. This study was designed to evaluate the safety and feasibility of the ulnar approach.From September 2004 through September 2006, 28 patients in a cohort study underwent cardiac catheterization by the transulnar approach. Patients were eligible if they had scheduled an elective cardiac catheterization or angioplasty procedure and displayed a palpable ulnar pulse and a positive reverse Allen's test (< 10 sec). Further, we enrolled only patients who had stable angina. After cannulation, a 5F or 6F introducer was placed inside the vessel, and cardiac catheterization or angioplasty was performed. The patients underwent clinical examination when discharged from the hospital and again at the 1-week follow up.Mean age, weight, and height of the patients were 60 +/- 14 years, 78 +/- 14 kg, and 148 +/- 55 cm, respectively, and 69% were men. Successful puncture was achieved in 93% (26/28), and in all 26 of these patients the procedure could be completed by the ulnar approach. The femoral approach was used for the remaining 2 patients. No cases of arterial spasm or loss of pulse were observed. Two patients had minor hematoma at the entry site. There were no cases of pseudoaneurysm, bleeding episodes requiring transfusion, or vascular perforation.We conclude that the transulnar approach is a safe and feasible alternative for diagnostic and therapeutic coronary intervention.

Effectiveness of the Amplatzer device for transcatheter closure of an ostium secundum atrial septal defect.

OBJECTIVE: To evaluate the effectiveness of the Amplatzer septal occluder in the treatment of ostium secundum atrial septal defects (OS ASDs). METHODS: Retrospective cohort study conducted between November 1998 and September 2005 involving 101 OS ASD transcatheter occlusion procedures in our institution. All procedures were conducted in the hemodynamic laboratory under general anesthesia with transoesophageal echocardiographic monitoring (TEE). Clinical and echocardiography assessments of the patients were conducted at 30 days, six months and on an annual basis. The results are presented as averages, standard deviations and percentages. Event-free survival was estimated using the Kaplan-Meier curve. RESULTS: From the 101 patients, 60 (59.4%) were females. Mean age, weight, height, body mass index and body surface area were, respectively: 24.3 +/- 18.31 years, 51.88 +/- 23.76 kg, 140.59 +/- 39.3 cm, 23.18 +/- 18.9 kg/m(2) and 1.24 +/- 0.21 m(2). The prevalence of interatrial septum aneurysms was 4.95%, and 98 cases had an isolated defect. ASD diameters were 21.47 +/- 6.96 mm using an angiography and 21.22 +/- 7.93 mm using a TEE. The average size of the implanted devices was 23.92 +/- 7.25 mm, ranging from 9 mm to 40 mm. The procedure time was 90.47 +/- 26.67 minutes and the average hospital stay was 2.51 +/- 0.62 days. Clinical and echocardiography follow-up was conducted at 12.81 +/- 8.41 months and all devices were securely anchored without any residual shunts. The procedure success rate was 93% (94/101). In five cases adequate deployment of the device was not possible and 2 patients presented residual ASD. No major complications occurred. CONCLUSION: The Amplatzer septal occluder is an effective OS ASD transcatheter treatment device.

Efetividade da prótese de Amplatzer™ para fechamento percutâneo do defeito do septo interatrial tipo Ostium Secundum / Effectiveness of the Amplatzer ™ device for transcatheter closure of an ostium secundum atrial septal defect

OBJETIVO: Avaliar a efetividade da prótese de Amplatzer® para tratamento de comunicação interatrial tipo ostium secundum (CIA OS). MÉTODOS: Estudo de coorte histórica entre novembro de 1998 e setembro de 2005, em que foram realizados 101 procedimentos para oclusão percutânea de CIA OS em nossa instituição. Os procedimentos foram efetuados no laboratório de hemodinâmica, sob anestesia geral e com monitorização por ecocardiografia transesofágica (ETE). Os pacientes foram acompanhados clinicamente e com ecocardiografia em 30 dias, seis meses e depois anualmente. O resultados são apresentados em média, desvio padrão e porcentual, e a sobrevida livre de eventos foi estimada pela curva de Kaplan-Meier. RESULTADOS: Dos 101 pacientes, 60 (59,4 por cento) eram mulheres. As médias para idade, peso, altura, índice de massa corporal e superfície corporal foram, respectivamente, de 24,3 + 18,31 anos, 51,88 + 23,76 kg, 140,59 + 39,3 cm, 23,18 + 18,9 kg/m², e 1,24 + 0,21 m². A prevalência de aneurisma do septo interatrial foi de 4,95 por cento, e 98 casos eram de defeito único. O diâmetro das CIAs foi de 21,47 + 6,96 mm pela angiografia e de 21,22 + 7,93 mm pela ETE. As próteses implantadas mediam 23,92 + 7,25 mm, variando de 9 mm a 40 mm. O tempo de procedimento foi de 90,47 + 26,67 minutos e a média de internação hospitalar, de 2,51 + 0,62 dias. Os seguimentos clínico e ecocardiográfico ocorreram com 12,81 + 8,41 meses e todas as próteses estavam bem ancoradas e sem shunt residual. O sucesso do procedimento foi de 93 por cento (94/101). Em cinco casos não se conseguiu liberação adequada do dispositivo e dois pacientes apresentaram CIA residual. Não foram registradas complicações maiores. CONCLUSÃO: A prótese de Amplatzer® mostrou-se efetiva para o tratamento percutâneo de CIA OS.

OBJECTIVE: To evaluate the effectiveness of the Amplatzer™ septal occluder in the treatment of ostium secundum atrial septal defects (OS ASDs). METHODS: Retrospective cohort study conducted between November 1998 and September 2005 involving 101 OS ASD transcatheter occlusion procedures in our institution. All procedures were conducted in the hemodynamic laboratory under general anesthesia with transoesophageal echocardiographic monitoring (TEE). Clinical and echocardiography assessments of the patients were conducted at 30 days, six months and on an annual basis. The results are presented as averages, standard deviations and percentages. Event-free survival was estimated using the Kaplan-Meier curve. RESULTS: From the 101 patients, 60 (59.4 percent) were females. Mean age, weight, height, body mass index and body surface area were, respectively: 24.3 ± 18.31 years, 51.88 ± 23.76kg, 140.59 ± 39.3cm, 23.18 ± 18.9kg/m² and 1.24 ± 0.21m². The prevalence of interatrial septum aneurysms was 4.95 percent, and 98 cases had an isolated defect. ASD diameters were 21.47 ± 6.96mm using an angiography and 21.22 ± 7.93 mm using a TEE. The average size of the implanted devices was 23.92 ± 7.25mm, ranging from 9mm to 40mm. The procedure time was 90.47 ± 26.67 minutes and the average hospital stay was 2.51 ± 0.62 days. Clinical and echocardiography follow-up was conducted at 12.81 ± 8.41 months and all devices were securely anchored without any residual shunts. The procedure success rate was 93 percent (94/101). In five cases adequate deployment of the device was not possible and 2 patients presented residual ASD. No major complications occurred. CONCLUSION: The Amplatzer™ septal occluder is an effective OS ASD transcatheter treatment device.